Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence.

Rohleder, Cathrin; Müller, Juliane K; Lange, Bettina; Leweke, F M

Rohleder, Cathrin; Müller, Juliane K; Lange, Bettina; Leweke, F M.

Afiliação

Rohleder C; Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim Germany.
Müller JK; Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim Germany.
Lange B; Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim Germany.
Leweke FM; Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim Germany.

Front Pharmacol ; 7: 422, 2016.

Article em En | MEDLINE | ID: mdl-27877130

Palavras-chave

CBD; animal models; clinical trials; psychosis; schizophrenia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google